Kaysen George A
Division of Nephrology, Department of Medicine, University of California, Davis, Davis, California 95616, USA.
Kidney Int. 2009 Aug;76(4):359-61. doi: 10.1038/ki.2009.205.
High-density lipoprotein (HDL) cholesterol level is low in dialysis patients. The HDL that is present is dysfunctional, failing to protect low-density lipoprotein (LDL) from oxidation and reduce levels of oxidized LDL. Addition of the orally absorbable amphipathic peptide 4-F to LDL obtained from dialysis patients protects LDL from oxidation in vitro and reduces the capacity of oxidized LDL to induce expression of monocyte chemoattractant protein-1 (MCP-1) by vascular endothelial function in culture, potentially providing a tool to reduce cardiovascular risk in dialysis patients.
透析患者的高密度脂蛋白（HDL）胆固醇水平较低。现有的HDL功能失调，无法保护低密度脂蛋白（LDL）免受氧化并降低氧化LDL的水平。将可口服吸收的两亲性肽4-F添加到从透析患者获得的LDL中，可在体外保护LDL免受氧化，并降低氧化LDL通过培养中的血管内皮功能诱导单核细胞趋化蛋白-1（MCP-1）表达的能力，这可能为降低透析患者的心血管风险提供一种手段。
